Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

• Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). Treatment guidelines propose dose escalation based on clinical assessments of disease response.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Benzamides

Clinical Trials as Topic

Disease-Free Survival

Drug Administration Schedule

Leukemia

Myeloid

Chronic-Phase

drug therapy

Piperazines

administration & dosage

Pyrimidines

administration & dosage

Survival Analysis

Treatment Outcome

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)